Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals

In this article:
  • Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline.

  • Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC.

  • The deal is centered around an actinium-225 labeled prostate-specific membrane antigen (PSMA) small molecule currently in pre-IND studies for prostate cancer.

  • Bayer has its portfolio of targeted alpha therapies, which includes Xofigo, a radium-based therapy approved to treat metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases, as well as an investigational conjugate platform based around thorium-227.

  • Price Action: BAYRY shares are down 0.78% at $15.89 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement